SYH2070
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 01, 2026
Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
(clinicaltrials.gov)
- P2 | N=18 | Recruiting | Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders
July 23, 2026
A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia
(clinicaltrials.gov)
- P2 | N=240 | Recruiting | Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Dyslipidemia • Mixed Hyperlipidemia
May 16, 2026
Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
(clinicaltrials.gov)
- P2 | N=18 | Not yet recruiting | Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
New P2 trial • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders
1 to 3
Of
3
Go to page
1